The diabesity health economic crisis - the size of the crisis in a European island state following a cross-sectional study by Cuschieri, Sarah et al.
RESEARCH Open Access
The diabesity health economic crisis—the
size of the crisis in a European island state
following a cross-sectional study
Sarah Cuschieri1* , Josanne Vassallo2, Neville Calleja3, Nikolai Pace1, Janice Abela2, Bader A. Ali2,
Fatemah Abdullah4, Elizier Zahra5 and Julian Mamo3
Abstract
Background: Diabetes type 2 and obesity are well-established global epidemics and contributors to clinical, social
and economic health burdens. The prevalence rates of these diseases are still on the rise among countries resulting
in a corresponding public health burden. The Mediterranean island of Malta, known for it’s high diabetes and
obesity rates, provides a good fundamental basis to portray the economical health burden of these diseases.
Method: A recent randomised stratified representative cross-sectional survey conducted in Malta tackling diabetes,
obesity and other determinants, was used to work out the population prevalence of these diseases. The cost
burden of diabetes and obesity, based on published data, was incorporated to the established population
prevalence rates, in order to estimate the Maltese economical burden. Projections to the year 2050 by a bottom-up
prevalence based design were performed.
Results: One eight of the Maltese adults (25 to 64 years) suffered from diabetes out of which approximately 10,000
adults were unaware of the disease. Alarmingly, more than a third of the Maltese population suffer from obesity.
The approximate health care costs (direct and indirect) for the diabetic adult population was of €29,159,217
(€21,994,676 - €38,919,121) annually, amounting to 3.64% (2.75–4.875%) of the total health expenditure in Malta.
The obesity cost burden was of €23,732,781 (€21,514,972-€26,049,204) annually contributing for 2.97% (2.69–3.26%)
of the total health expenditure. The projected prevalence and costs for 2050 exhibited an estimated cost burden
increase of €33,751,487 (€25,458,606–€45,048,473) for the diabetes mellitus population and €46,532,294
(€42,183,889–€51,074,049) for the obese population. These projected cost burdens are expected to increase
exponentially the total health care expenditure in Malta by 2050.
Conclusion: Having an understanding of the prevalence and the economic cost burden of diabetes and obesity
within a country, along with projections of the expected burden will enable policy and public health officials to
clearly visualize this growing problem. It also helps in establishing effective preventive strategies and screening
programs targeting these epidemics.
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Background
The global obesity and diabetes mellitus type 2 preva-
lence rates have increased exponentially over recent
years [1, 2]. Globally an estimated 2 billion people are
overweight, a third of which being obese [1]. The in-
creasing prevalence of obesity is predicted to lead to
other chronic related diseases [3]. The link between
obesity and type 2 diabetes is well established through
the development of obesity related insulin resistance.
It follows that the prevalence of the two diseases is
directly proportional [3]. However, only about 20–25%
of the overweight and obese population is expected to
develop diabetes [4]. Both diseases lead to heavy in-
creases in clinical, social and economic health bur-
dens as well as to increments in morbidity and
mortality [5, 6]. They also impact on employment and
productivity, both of which have significant direct im-
pacts on a country’s productivity and economical
growth [7].
Malta is a European island nation in the middle of the
Mediterranean Sea with a total population of 425,384
(median age 40.9 years). Its history is littered with di-
verse dominating powers and shifts in its culture
throughout the centuries. Up to 150 years ago, the popu-
lation followed a Mediterranean lifestyle and diet, al-
though this has now shifted to a more Westernized
lifestyle and diet [8]. The World Health Organization
(WHO) conducted the last Maltese national prevalence
study in Diabetes in 1981 [9]. Subsequently, a health
examination pilot study was conducted on the Island in
2010. However, the latter study had a small sample size
(n = 221) and offered only a glimpse of the actual dia-
betes and obesity burden [10]. This has led to Maltese
policies and economic burden extrapolations being
based on outdated sources, despite strong emigra-
tional, cultural and lifestyle changes over recent de-
cades [8]. Between 2014 and 2016, the University of
Malta “SAHHTEK” (Your Health) cross-sectional
study was conducted. This provided valid, updated
prevalence rates, through which the diabetes mellitus
type 2 and obesity health burden in Malta could be
established. The aim of this study was to establish the
current (for 2016) prevalence and economic burden
of diabetes type 2 and obesity in Malta. The objectives
were: 1) to establish the body mass distribution within the
diabetic sub-population by age and gender; 2) to estimate
the projected total population prevalence of type 2 dia-
betes and obesity in Malta for 2050; 3) estimate the eco-
nomic burden of diabetes and obesity for the year 2050
and; 4) provide evidence based data for policy makers to
target and implement prevention strategies concerning
these non-communicable diseases. This study will serve as
a fundamental basis for the burden estimation in neigh-
bouring Mediterranean countries.
Method
A cross-sectional health examination survey was con-
ducted between November 2014 and January 2016. The
sample population was obtained from the national regis-
try after performing randomization and stratification of
the data by age (18 to 70 years) and gender [11]. The
data was further stratified according to residence local-
ity, to represent an approximate 1% population from
each Maltese town. The total randomized and stratified
population (n = 4,000) was invited to participate in a
health examination survey set up in every Maltese town
through an invitation letter sent out via post. The health
examination survey consisted of a validated question-
naire and health examination including weight and
height as well as blood letting for fasting blood glucose
and lipid profile.
The measured weight and height was used to calculate
the body mass index (BMI) by dividing the weight (in kilo-
grams - kg) over the height squared (meters squared - m2).
Those participants with a BMI <24.99Kg/m2 were
considered as normal BMI; 25–29.99Kg/m2 as over-
weight and >30Kg/m2 as obese [12]. Participants were
considered as suffering from ‘previously known dia-
betes mellitus’ if they gave a medical history of dia-
betes or were on oral hypoglycemic agents, irrelevant
of the measured fasting blood glucose. Meanwhile, all
those obtaining measured fasting blood glucose above
7 mmol/L were considered as newly diagnosed dia-
betics [13].
The diabetes population (total) was defined as the sum
of the previously known diabetes mellitus participants to
the newly diagnosed participants. Prevalence rates of
diabetes (by gender and 10-year age groups) were calcu-
lated by dividing the total diabetes population by the
total participants who attended the study. The preva-
lence rate was applied to the latest officially recorded
total Maltese population demographic statistics to obtain
the overall population with diabetes [12]. Similar calcula-
tions were used to estimate the prevalence rates of those
with normal, overweight or obese status in the Maltese
population [14, 15]. Sensitive analyses based on the con-
fidence intervals of the prevalence rates were preformed.
The study only considered type 2 diabetes mellitus indi-
viduals. The Research Ethics Committee of the Faculty
of Medicine and Surgery at the University of Malta to-
gether with the Information and Data protection com-
missioner gave their consent for this study.
The estimated cost burden for diabetes in Malta was
calculated by applying the established prevalence rate of
newly diagnosed diabetics and that for the previously
known diabetics (individually) to the cost burden found
in the literature for each diabetes subgroup. The cost
burden for the newly diagnosed diabetics population was
based on estimates performed by Zhang Y et al. (2009)
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in the USA after adjusting for the gross domestic poduct
(GDP) per capita and by adjusting for deflation be-
tween the USA and Malta [16]. The cost burden for the
previously known diabetes population was obtained
from published International Diabetes Federation (IDF)
data on Malta [17]. The cost attributed for the obese
population was obtained from a study conducted in
Malta by the Department of Health Information and
Research in 2008, based on the 2008 European Health
Information Survey, after 2% compound interest per
annum was performed [18].
Projections to the year 2050 were performed by a
bottom-up prevalence-based design for diabetes and for
obese rates (1981 to 2014–2015 surveys). For purposes
of comparative and statistical analysis, only the subgroup
of adults between 25 and 64 years of age were utilized
from SAHHTEK. This was required to keep a valid
comparison with the 1981 study. By hypothesizing that
no other factors distorted linear projections for both
disease prevalence rates, an estimation of the affected
population and their economic burden was established
based on the EUROSTAT 2050 population projections
for Malta [19]. Statistical analysis including chi squared
was calculated by means of IBM SPSS version 21.
Demographic and lifestyle data was gathered by means
of a combination of validated tools used during the
“SAHHTEK” survey [20–22].
Results
The sample population that attended the study (response
rate of 49% p = <0.05) was weighted according to age,
gender and locality. This enabled the data to be statisti-
cally representative of the whole population of Malta as
well as to take in consideration the non-responders.
After statistically weighting the sample, the final popula-
tion dataset was of 3,947 (1998 males, 1949 females).
Out of which, 10.39% (95% CI: 9.47–11.38) suffered
from diabetes, among which 6.31% (95% CI: 5.59–7.11)
were previously known diabetics and 4.08% (CI: 3.50–
4.74) were newly diagnosed. 69.77% (95% CI: 68.32–
71.18) of the total population was found to be either
overweight or obese (Table 1) with a heavy male pre-
dominance. The diabetic population was predominantly
either overweight or obese (92.20% CI 95%: 89.16–94.45)
as seen in Table 1.
It was noted that younger (<55 years) diabetics were
predominately (54% CI 95%: 44.30–63.12%) new (un-
known) diabetics, while for those aged 55 and over,
only 34% (CI 95%: 29.21–39.80) were new diabetics
with the vast majority (66% CI 95%: 60.20–70.79) being
known diabetics. This finding is in keeping with pub-
lished data evaluating the degree of diabetes awareness
between the 1981 and 2010 examination surveys con-
ducted in Malta [23].
Further subdivision of the diabetic population by age
and body weight revealed younger diabetics (<55 years)
to be predominately obese (50% CI 95%: 40.56–59.44) or
overweight (46% CI 95%: 36.88–55.70), with only 4% (CI
95%: 2–8.9) having normal weight. Conversely, a higher
proportion of older diabetics (≥55 years) were found to
belong to the normal weight category (9% CI 95%: 6.37–
12.50) with 57% (CI 95%: 51.50–61.61) of these found
Table 1 BMI prevalence rates by population (diabetic and non-diabetic) population
BMI category
Total Population Normal % (95% CI) Overweight % (95% CI) Obese % (95% CI)
Total (n = 3947) 30.26% (28.84–31.70) 35.66% (34.17–37.15) 34.11% (32.64–35.60)
Male (n = 1998) 23.72% (21.91–25.64) 39.39% (37.27–41.55) 36.89% (34.80–39.03)
Female (n = 1949) 36.94% (34.83–39.11) 31.81% (29.79–33.91) 31.25% (29.23–33.34)
p-value* 0.0001 0.0001 0.0001
Diabetic Population Normal % (95% CI) Overweight % (95% CI) Obese % (95% CI)
Total (n = 410) 7.8% (5.55–10.84) 36.83% (32.30–41.60) 55.37% (50.53–60.11)
Male (n = 274) 8.39% (5.61–12.33) 39.78% (34.16–45.68) 51.82% (45.92–57.57)
Female (n = 136) 6.62% (3.36–12.26) 30.88% (23.71–39.10) 62.50% (54.12–70.19)
p-value* 0.73 0.84 0.327
Non-Diabetic Population Normal % (95% CI) Overweight % (95% CI) Obese % (95% CI)
Total (3537) 32.85% (31.31–34.42) 35.51% (33.76–36.90) 31.64% (30.12–33.19)
Male (1724) 26.16% (24.14–28.29) 39.33% (37.05–41.65) 34.51% (32.31–36.79)
Female (n = 1813) 39.22% (36.99–41.48) 31.88% (29.78–34.06) 28.9% (26.86–31.03)
p-value* 0.0001 0.0001 0.0001
*Chi squared between each BMI category against gender
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obese and 34% (CI 95%: 28.59–39.13) found to be over-
weight (p = 0.001).
On incorporating the established prevalence rates and
their corresponding confidence intervals from this study
to the Maltese population, an estimate of the present
total population burden of diabetes mellitus and obesity
by 10-year age groups and gender was established [14].
Table 2 shows the estimated total Maltese diabetes
population by gender and age.
In the Maltese adult population between 25 and 64 years
of age, approximately 20,000 adults suffer from diabetes mel-
litus type 2. Out of which, approximately 10,000 adults suffer
from diabetes and are yet unaware of it, with a male predom-
inance (approx. 6,000). On comparing the Maltese diabetes
population to the IDF Atlas (7th Edition) European diabetes
population, the Maltese diabetic population contributes to an
approximate 0.03% of diabetes within Europe [2]. This preva-
lence percentage is an estimate comparison since the adult
population age groups for the IDF (20 to 79 years) was differ-
ent when compared to SAHHTEK study (25 to 64 years).
On the other hand, approximately 82,000 of the
233,136 adults (35% of the adult population) in this age
category (25–64 years) in Malta are obese, with a
persisting male predominance (approx. 46,000) (Table 3).
This ranks the Maltese population as the most obese
country in the Mediterranean (Italy – 10.5%; Cyprus –
13.9%; Greece – 16.9%) and in Europe [24].
Estimating the cost burden (both direct and indirect)
of an undiagnosed diabetic to be approximately €1,052
per person per year (6.67% of the annual mean salary in-
come per person in Malta), the annual burden for the
entire population (25 to 64 years) was estimated at
€9,755,196 (€7,065,232–€13,582,372), which contributes
to 1.22% (0.88–1.70%) of the total health expenditure for
Malta [16, 25]. The total health expenditure for Malta
(for 2016) is approximately €800,000,000 [25]. The direct
medical costs include hospital inpatient costs, physician
care, emergency care, outpatients care and prescriptions,
while the indirect costs included absence from work, re-
duced work performance and productivity [16]. Con-
versely, a known diabetic person’s disease cost burden
was approximately €1,887 per person annually (11.96%
of the annual mean salary income per person in Malta),
attributing to an annual health burden of €19,404,021
(€14,929,944–€25,336,749) for the entire population (25
to 64 years) [17]. This is consistent with 2.43% (1.87–
Table 2 Estimation of the diabetes mellitus population burden by applying the prevalence rates to Maltese population data by age
and gender
Maltese Population Diabetes Prevalence
Age Total Maltese Population by agea Total (CI) Previously Known (CI) Unknown Diabetics (CI)
25–34 62,180 404 (143–964) 404 (143–964)
35–44 56,575 2,489 (1,765–3,491) 933 (515–1,641) 1,556 (996–2,399)
45–54 55,113 5,054 (4,007–6,332) 2,712 (1,962–3,726) 2,337 (1,642–3,296)
55–64 59,268 11,611 (10,052–13,347) 6,638 (5,435–8,060) 4,976 (3,935–6,253)
Total 233,136 19,558 (15,967–24,134) 10,283 (7,912–13,427) 9,273 (6,716–12,911)
Age Male Maltese Population by agea Maltese Male Population Diabetes Prevalence
Total (CI) Previously Known (CI) Unknown Diabetics (CI)
25–34 32,359
35–44 29,143 1,781 (1,195–2,611) 667 (332–1,271) 1,113 (664–1,821)
45–54 27,728 4,204 (3,252–5,368) 2,426 (1,708–3,397) 1,777 (1,173–2,651)
55–64 29,585 6,935 (5,784–8,236) 3,763 (2,896–4,840) 3,172 (2,379–4,189)
Total 118,815 12,920 (10,231–16,216) 6,856 (4,937–9,507) 6,062 (4,216–8,661)
Age Female Maltese Population by agea Maltese Female Population Diabetes Prevalence
Total (CI) Previously Known (CI) Unknown Diabetics (CI)
25–34 29,821 397 (143–945) 397 (143–945)
35–44 27,432 658 (313–1,300) 247 (49–749) 411 (148–977)
45–54 27,385 1,060 (633–1,733) 424 (173–934) 630 (318–1,210)
55–64 29,683 4,625 (3,648–5,806) 2,853 (2087–3,856) 1,772 (1,178–2,624)
Total 114,321 6,740 (4,736–9,785) 3,524 (2,309–5,539) 3,210 (1,787–5,756)
CI − 95% Confidence intervals
a2013 Malta Demographic Report
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3.17%) of the Maltese total health expenditure. There-
fore the global cost burden of diabetes mellitus for the
Maltese health system is approximate a total of
€29,159,217 (€21,994,676–€38,919,121) annually. The
diabetes cost burden contributes to 3.65% (2.79–4.87%)
of the total health expenditure (state and private expend-
iture) for Malta [25]. On the other hand, the attributed
cost burden (included inpatient stay, day patient stay,
general practitioner and specialist consultations but not
medication and surgical procedures) for obesity in Malta
(2% compound interest per annum), was estimated to be
€23,732,781 (€21,514,972–€26,049,204) for the year 2016
[18]. The obesity cost burden contributes to 2.97%
(2.69–3.26%) of the total health expenditure for Malta
[25]. Therefore the total ‘diabesity’ cost burden for
Malta, in 2016, is an approximate total of €52,891,998
(€43,509,648–€64,968,325) which amounts to 6.61%
(5.44–8.12%) of the Malta’s total health expenditure.
The projected EUROSTAT 2050 Maltese population (25
to 64 years) was incorporated within the projected preva-
lence rates for diabetes and obesity rates as seen in Table 4.
On incorporating these projected prevalence rates within
the projected cost burden (2% compound interest per
annum from the 2016 costs) for diabetes and obesity, we
were able to estimate the likely economic burden caused by
these diseases for 2050 (Table 5). The total adult population
(25 to 64 years) projected for 2050 appears to decrease from
the current 2016 adult population. Meanwhile, the diabetes
and obese population will increase by approximately 28 and
15% respectively by 2050. The economic burden is expected
to increase in association with this disease burden. An expo-
nentiation of 1.2 in the diabetes cost burden and exponen-
tiation of 2 in obese cost burden from the current (2016)
is expected to occur by 2050. This contributes to an
estimated cost burden of €33,751,487 (€25,458,606–
€45,048,473) for diabetes mellitus and €46,532,294
(€42,183,889–€51,074,049) for the obese. Therefore the
estimated total cost burden for 2050 for diabetes mellitus
type 2 and obesity would amount to one-eight of the
current (2016) total health expenditure (€800,000,000).
Discussion
Diabetes mellitus type 2 and obesity prevalence rates are
on the rise with the majority of diabetic patients being
obese [26]. This is observed in the current study where
the bulk of the Maltese population was either overweight
or obese. Apart from this, a tenth of the total adult
population (18 to 70 years) suffered from diabetes melli-
tus type 2. Another worrying feature is that the majority
of the Maltese diabetic population was obese. The pro-
jected Maltese estimates for 2050, also exhibit an expo-
nential increase in the obese population, along with a
drastic increase in diabetes mellitus. Although diabetes
might not develop in all those who are obese, the accu-
mulation of adipose tissue initiates a cascade of
Table 3 Estimation of the obese population burden by
applying the prevalence rates to Maltese population data by
age and gender
Maltese Population
Age Total Maltese Population by agea Obese BMI (CI)
25–34 62,180 15,968 (14,127–17,951)
35–44 56,575 18,523 (16,644–20,497)
45–54 55,113 22,315 (20,386–24,299)
55–64 59,268 25,260 (23,239–27,328)
Total 233,136 82,066 (74,397–90,076)
Age Male Maltese Population by agea Obese BMI (CI)
25–34 32,359 9,569 (8,187–11,076)
35–44 29,143 12,310 (10,914–13,750)
45–54 27,728 12,611 (11,172–14,078)
55–64 29,585 11,730 (10,349–13,171)
Total 155,996 46,220 (40,621–52,075)
Age Female Maltese Population by agea Obese BMI (CI)
25–34 29,821 6,423 (5,272–7,747)
35–44 27,432 5,914 (4,792–7,212)
45–54 27,385 9,881 (8,615–11,222)
55–64 29,683 13,568 (12,111–15,052)
Total 114,321 35,786 (30,791 - 41,234)
CI - 95% Confidence intervals
a2013 Malta Demographic Report
Table 4 Projected prevalence rates of diabetes and obese population for 2050 in Malta
Age 2050 Projected Total Maltese
Population by agea
Projected Diabetes & Obesity Prevalence for 2050
Total Diabetes (CI) Obese (CI)
25–34 56,709 601 (255–913) 21,810 (19,791–23,829)
35–44 52,965 3,813 (2,961–4,666) 21,175 (19,650–22,685)
45–54 53,819 5,457 (4,698–6,211) 22,970 (21,361–24,579)
55–64 62,342 15,199 (14,014–16,153) 28,079 (26,882–29,295)
Total 225,835 25,071 (21,929–27,943) 94,034 (87,684–100,388)
CI - 95% Confidence interval
aDemographic Data 2013
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metabolic events. These in turn have the ability to initiate
or exacerbate insulin resistance in those more predis-
posed. All this can subsequently lead to the development
of various metabolic diseases including hypertension, dys-
lipideamia and cardiovascular disease [27].
Tackling the obesity epidemic in its own right is of ut-
most importance in order to prevent further obesity-
related illnesses that are contributing not only to a de-
crease in the quality of life and mortality of many, but
also attributing to an estimated 8 to 10% of the total
health expenditure in many European countries [28].
In Malta, the cost burden attributed to overweight-
obesity was estimated to be 5.7% of total health ex-
penditure in 2008 [18]. Considering that only the obes-
ity burden was evaluated in the current study, one
cannot directly compare to the 2008 (Malta) health ex-
penditure. However, no drastic exponential increase
appears to have occurred. On comparing the current
obesity impact on the total health expenditure to other
European countries, Malta relates well to the obesity
related expenditure reported [28].
The International Diabetes Federation estimated the
2009 cost burden for diabetes mellitus to contribute to 11%
of the total health expenditure in Malta [29]. Our results
showed that diabetes (direct and indirect) cost burden on
the total health expenditure has decreased by approxi-
mately three-fold from the IDF estimate for Malta. Accord-
ing to the IDF, diabetes mellitus type 2 accounts for 5 to
20% of the majority of the countries’ total health care ex-
penditure, which is in keeping to the study’s results [2]. In
Malta, diabetes appears to have the same burden effect on
the total health care expenditure as other countries.
The diabetes and obesity epidemics present as a
great burden of care and an economic challenge to the
Maltese population from the relatively young age of
35 years onwards [30]. In fact, extrapolations from the
current (2016) obese and diabetes burden to 2050, ex-
hibit a major health care concern for Malta, especially
with the expected high diabetes prevalence rise and re-
lated economical costs. It is questionable whether the
overall health budget will also swell proportionately,
given the current economic situation. This is more so
considering that by 2050, diabetes and obesity health
burdens are expected to amount to one-eight of the
current (2016) total health care expenditure. The
planned Malta EU Presidency for 2017 (January to
June) reflects the obesity burden and is planned to
tackle Childhood obesity. Considering that a substan-
tial proportion of the young population (<55 years)
was found to have unknown diabetics and an increased
body weight (obese > overweight), this brings forward
the need for immediate action. The higher the obesity
and diabetes prevalence rates, the higher the expected
hospitalization rates and other related costs [5]. It is
well established that the risk of co-morbidity increases
with the increase in body mass index (BMI) [31]. Per
capita costs reach their maximum among the obese
population [32]. This phenomenon has been recorded
in various European countries [33–35]. It is essential
that health services in Malta and elsewhere in Europe
embark on effective preventive strategies and oppor-
tunistic screening to target these conditions from an
early age, before the disease has been ingrained for too
long [23]. Although this could impose an even larger
health budget request on the country, such early action
could help decrease the health burden contributed to
diabetes, obesity and their associated complications. In
fact, disease prevention should always be the primary
target of any health management strategy.
Study limitations
The response rate obtained was 49%. This can present
as a potential non-response bias but the data was statis-
tically weighted according to age, gender and locality in
order to overcome this potential bias. The study does
not cover the whole population but only a subset of the
adult population. Since the prevalence of diabetes is sub-
stantial within the elderly population, costs may be
affected by other underlying comorbidities. General
demographic data was based on the latest published re-
ports from 2013. The health cost for undiagnosed dia-
betes was based on a U.S. study, as no data was available
for the Maltese population, although the GPD per capita
for both countries was taken in consideration. The cost
of illness data was obtained from secondary sources and
this may affect the validity of the cost of illness in the
Maltese health care setting. The previously known dia-
betes cost was obtained from the 2015 IDF estimated
costs for Malta but no detailed description was available
to the health care costs constitution. All costs from the
Table 5 Comparison of the total cost burden for diabetes and obese population for 2016 and those projected for 2050
Maltese Population (25 to 64 years)
Total Diabetes Obese
2016 Costs €29,159,217 €23,732,781
(€21,994,676–€38,919,121) (€21,514,972–€26,049,204)
2050 Projected Costs with 2% Compound interest per annum €33,751,487 €46,532,294
(€25,458,606–€45,048,473) (€42,183,889–€51,074,049)
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secondary sources lacked confidence intervals; therefore
sensitivity analysis could not be performed on the unit
costs. Comparisons with other studies were difficult due
to the fact that the age groups and the total population
samples were different from the current study and not
comparable. Projections for the year 2050 were based on
current conditions with an assumption that all demo-
graphic and risk factors would continue at their current
rates. The economical burden excluded society burden
including intangibles from pain and decreased quality of
life, as well as the impact on caregivers.
Conclusion
The study explored the present disease burden and eco-
nomic costs for diabetes and obesity in Malta as well as
those projected for 2050. A substantial prevalence and
economical burden increase was estimated for 2050. The
current Maltese health care expenditure for both dis-
eases was similar to other European countries estimates.
The data obtained should encourage policy makers to
further explore the situation and bring forward pre-
ventative strategies considering the present ‘diabesity’
burden and the expected exponential increase. Imple-
menting early screening tests for diabetes and obesity
might be one of the best strategies to counteract the epi-
demic and reduce the overall costs.
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